SAN DIEGO, CA--(Marketwire - April 21, 2008) - Lpath, Inc. (OTCBB: LPTN), the category leader in bioactive-lipid-based therapeutics, initiated its first Phase 1 clinical trial on April 16, 2008 by dosing a cancer patient with its lead drug candidate, ASONEP™, a monoclonal antibody targeting sphingosine-1-phosphate (“S1P”). ASONEP is the systemic version of sonepcizumab and the humanized version of Sphingomab™.
